Company: KROS
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001664710-25-000089
Chunk: 225

Company: Keros Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 1
Chunk 225
---
ulated deficit(458,304)(568,779)Total stockholders' equity703,580 571,553 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$742,783 $615,886 

See notes to condensed consolidated financial statements.

5

KEROS THERAPEUTICS, INC. 

Condensed Consolidated Statements of Operations 

(In thousands, except share and per share data) 

(Unaudited)

THREE MONTHS ENDED SEPTEMBER 30,NINE MONTHS ENDED SEPTEMBER 30,2025202420252024REVENUE:Service and other revenue$4,262 $388 $38,321 $508 License revenue10,000 — 205,355 — Total revenue14,262 388 243,676 508 OPERATING EXPENSES:Research and development(19,519)(49,225)(111,731)(127,998)General and administrative(10,127)(9,820)(35,106)(30,089)Total operating expenses(29,646)(59,045)(146,837)(158,087)INCOME (LOSS) FROM OPERATIONS(15,384)(58,657)96,839 (157,579)OTHER INCOME (EXPENSE), NETDividend income6,933 5,793 20,845 16,977 Other expense, net(253)(92)(812)(725)Total other income, net6,680 5,701 20,033 16,252 Income (loss) before income taxes(8,704)(52,956)116,872 (141,327)Income tax (provision) benefit1,424 — (6,397)— Net income (loss)$(7,280)$(52,956)$110,475 $(141,327)Net income (loss) attributable to common stockholders — basic and diluted (Note 8)$(7,280)$(52,956)$110,475 $(141,327)Weighted-average shares of common stock outstanding — basic40,623,36437,590,72740,598,77736,463,906Weighted-average shares of common stock outstanding — diluted40,623,36437,590,72741,202,37136,463,906Net income (loss) per share of common stock — basic$(0.18)$(1.